Blocking T Cells Protects Memory Centers in Alzheimer's Mice Without Clearing Tau
Washington University researchers blocked the immune receptor CXCR3 in tau-affected mice, preserving about 40% more memory-region tissue even with tau left in place.
Summary
Alzheimer's brain damage may stem less from toxic tau itself and more from the immune system's reaction to it. Researchers at Washington University School of Medicine in St. Louis tested this in mice with Alzheimer's-like tau buildup. They gave an antibody that blocks CXCR3, a protein that helps T cells, a type of immune cell, enter the brain. After several months, T cells in the brain fell by about half. Treated mice kept roughly 40% more tissue in memory-related regions and did better on a memory test, even though tau levels were unchanged. Current approved drugs, lecanemab and donanemab, clear amyloid and can slow decline, but they have not been shown to stop neurons from dying. This work points to a different strategy: calming harmful immune activity to protect neurons. The results are from mice, so human benefit remains unproven. The study was published in Neuron.
Detailed Summary
Alzheimer's disease and related tauopathies destroy neurons, memory, and independence, and no current treatment has been shown to stop that cell loss. Approved antibody drugs, lecanemab and donanemab, remove amyloid plaques and can slow cognitive decline, but they do not prevent neurons from dying. They also do nothing for primary tauopathies, in which tau accumulates without amyloid. That gap is why a new strategy matters.
Researchers at Washington University School of Medicine in St. Louis, led by David Holtzman, built on evidence that the immune response to tau, rather than tau alone, drives much of the damage. A 2023 Nature study from the lab showed that T cells enter the brains of mice with tau pathology and cluster where tau is densest, contributing to neurodegeneration. A related Nature Neuroscience paper suggested the signals directing these T cells originate in lymph nodes outside the brain.
In the new Neuron study, the team treated mice with tau accumulation similar to that in Alzheimer's using an antibody against CXCR3, a protein that helps T cells enter the brain. After several months, brain T cell numbers dropped by about half. Treated animals kept roughly 40% more tissue in memory-related regions and performed better on a memory test than untreated animals. Tau levels did not change, which supports the idea that limiting the immune reaction can protect neurons even when the toxic protein remains.
For readers, this is early-stage science, not an available therapy. It suggests future treatments might combine amyloid or tau clearance with approaches that tame harmful neuroimmune activity, and that it could help people with primary tauopathies.
Caveats are significant. The work was done in mice, and mouse models only partly capture human disease. T cells also defend against infection and cancer, so long-term safety of blocking their brain entry is unknown. Human trials would be needed to confirm any cognitive or functional benefit.
Key Findings
- Blocking CXCR3 with an antibody cut T cells in the brains of tau-affected mice by about half.
- Treated mice kept roughly 40% more tissue in memory-related brain regions than untreated mice.
- Memory test performance improved even though accumulated tau levels did not change.
- Findings suggest immune reaction to tau, not tau alone, drives much of the neuron loss.
- Lecanemab and donanemab slow decline but have not been shown to prevent neuronal death.
Methodology
This is a university press-release news report on a peer-reviewed mouse study published in Neuron. The source, Washington University in St. Louis, is credible, and the senior author is quoted. Evidence is preclinical, with no human data.
Study Limitations
Results come from mouse models, which imperfectly mimic human Alzheimer's, and the excerpt lacks details on sample size, dosing, and safety. Blocking T cell entry could affect immune surveillance, and the long-term effects are unknown. Verify the details in the original Neuron paper.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: